MedPath

Management of Hypertension through Pippalyadi Ayurvedic yog

Not yet recruiting
Conditions
Essential (primary) hypertension. Ayurveda Condition: HYPERTENSION, (2) ICD-10 Condition: I10||Essential (primary) hypertension. Ayurveda Condition: uchharaktachap,
Registration Number
CTRI/2021/01/030220
Lead Sponsor
Dr Sarvepalli Radhakrishanan Rajasthan Ayurved University jodhpur
Brief Summary

This trial will be done for compare the clinical efficacy of pippalyadi yog and sarpagandhadi ghan vati in the management of uccharaktchap .Total 40 patient which are divided  in to two groups( 20 patient each),Group A  patient will take pippalyadi yog 1 gram thrice in a day and group B patients will take sarpagandhadi ghan vati thrice in a day with luke warm water .

at present time hypertension is a common problem .it does not  affect only our heart although many other diseases.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Patient having the symptoms raised blood pressure .
  • patient willing to sign the consent forms.
  • patient having blood pressure upto 160/100 mmhg.
Exclusion Criteria
  • 1.Open and randomized clinical age less than 25 years and more than 75 years.
  • 2.patients having blood pressure >160/100mmhg.
  • 3.patient having a history of untreated thyroid disorder and drug addiction.
  • pregnant women and lactating mother.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement in subjective and objective parameters.60 days
Secondary Outcome Measures
NameTimeMethod
To find out the comparative efficacy of the treatment in both groups.60 days

Trial Locations

Locations (1)

Dr. Sarvepalli Radhakrishnan Ayurved University hospital

🇮🇳

Jodhpur, RAJASTHAN, India

Dr. Sarvepalli Radhakrishnan Ayurved University hospital
🇮🇳Jodhpur, RAJASTHAN, India
dr kusum gehlot
Principal investigator
08058513105
gahlotk42@gamil.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.